Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    mesothelioma finland
Previous Study | Return to List | Next Study

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02610140
Recruitment Status : Completed
First Posted : November 20, 2015
Results First Posted : July 17, 2020
Last Update Posted : November 4, 2020
Sponsor:
Collaborator:
ImmunoGen and MorphoSys
Information provided by (Responsible Party):
Bayer

Brief Summary:

The main purpose of the 15743 study is to assess efficacy and safety of anetumab ravtansine versus vinorelbine in progression free survival in patients with stage IV mesothelin overexpressing malignant pleural mesothelioma (MPM).

210 eligible patients will be randomized to receive either anetumab ravtansine every three weeks or weekly vinorelbine.

Treatment will continue until centrally confirmed disease progression or until another criterion is met for withdrawal from the study. Patients will enter follow up phase to capture safety and endpoint data as required.

Efficacy will be measured by evaluating progression free survival from randomization. Radiological tumor assessments will be performed at defined time points until the patient's disease progresses.

Blood samples will be collected for safety, pharmacokinetic and biomarker analysis. Archival or fresh biopsy tissue may also be collected for central pathology review and biomarkers.


Condition or disease Intervention/treatment Phase
Mesothelioma Drug: Anetumab ravtansine (BAY94-9343) Drug: Vinorelbine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 248 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients With Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-based Chemotherapy
Actual Study Start Date : December 3, 2015
Actual Primary Completion Date : May 31, 2017
Actual Study Completion Date : September 6, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Mesothelioma

Arm Intervention/treatment
Experimental: BAY94-9343
Drug Anetumab ravtansine given Intravenously (IV)
Drug: Anetumab ravtansine (BAY94-9343)
Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.

Active Comparator: Vinorelbine
Drug Vinorelbine given Intravenously
Drug: Vinorelbine
Starting dose: 30mg/m^2 administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.




Primary Outcome Measures :
  1. Progression-free Survival (PFS), [95% CI] [ Time Frame: From randomization till approximately 117 PFS events observed, up to approx. 30 months (data cut-off: 31-May-2017) ]
    Progression-free survival (PFS), defined as time from randomization until disease progression according to mRECIST (Modified Response Evaluation Criteria in Solid Tumors) for Malignant pleural mesothelioma (MPM) per blinded central radiology review, or death. Only descriptive analysis of OS was repeated in the follow-up period.


Secondary Outcome Measures :
  1. Overall Survival (OS), [95% CI] [ Time Frame: Up to approx. 40 months (data cut-off: 06-Apr-2018) - Time from randomization until death from any cause; one-sided log-rank test stratified by time to progression (TTP) on first line treatment. ]
    Overall survival (OS) was defined as time from randomization until death from any cause.

  2. Objective Response Rate (ORR) [ Time Frame: up to approx. 30 months (data cut-off: 31-May-2017) - Time from randomization until death from any cause. ]
    A patient is a responder if the patient has a confirmed best tumor response on-study of CR (Complete response) or PR (Partial response), as determined by the central radiological reviewer per mRECIST criteria. ORR in each treatment arm was defined as the number of responders divided by the number of randomized patients. A responder was a patient who had a confirmed best tumor response on-study of CR or PR, as determined by the central radiological reviewer per mRECIST criteria.

  3. Disease Control Rate (DCR) [ Time Frame: Up to approx. 40 months (data cut-off: 06-Apr-2018) - Time from randomization until death from any cause. ]
    A patient has disease control if the patient has a best tumor response on-study of CR, PR, or SD (Stable disease). DCR was defined as a percentage of patients achieving CR, PR, or SD per mRECIST criteria, as determined by the central radiological reviewer. DCR was calculated in each treatment arm as the number of patients with disease control (a best tumor response on-study of CR, PR, or SD) divided by the number of randomized patients.

  4. Duration of Response (DOR) [ Time Frame: Up to approx. 40 months (data cut-off: 06-Apr-2018) - Time from randomization until death from any cause. ]
    DOR was defined in responders as the time from central documentation of tumor response date of first response in the confirmation sequence) to the earlier of disease progression as determined by the central radiological reviewer, or death without centrally documented progression. A responder was a patient who had a confirmed best tumor response on-study of CR or PR, as determined by the central radiological reviewer per mRECIST criteria.

  5. Durable Response Rate (DRR) [ Time Frame: Up to approx. 40 months (data cut-off: 06-Apr-2018) - Time from randomization until death from any cause. ]
    A durable responder was a responder (i.e. confirmed best tumor response on study of CR or PR) with duration of response of 180 days or more.

  6. Percentage of Participants With Confirmed Improvement of Symptoms Characteristic of Mesothelioma [ Time Frame: up to approx. 30 months (data cut-off: 31-May-2017) ]
    Improvement rate of symptoms characteristic of mesothelioma was defined as the number of patients with confirmed improvement of symptoms characteristic of mesothelioma (based on the MD Anderson Symptom Inventory-Malignant Pleural Mesothelioma, MDASI-MPM), divided by the number of patients evaluable for improvement of symptoms characteristic of mesothelioma.

  7. Time to Worsening of Symptoms Characteristic of Mesothelioma [ Time Frame: up to approx. 30 months (data cut-off: 31-May-2017) ]
    Time to worsening of symptoms characteristic of mesothelioma (TTWS) was defined in patients evaluable for assessing worsening of symptoms, as the time from randomization until the first worsening of symptoms characteristic of mesothelioma. Patients who died, were lost to follow-up, or ended (MD Anderson Symptom Inventory-Malignant Pleural Mesothelioma) MDASI-MPM assessments without confirmed worsening of symptoms were censored at the date of their last MDASI-MPM assessment with a non-missing (Composite Symptom Score) CSS.

  8. Time to Worsening of Pain [ Time Frame: up to approx. 30 months (data cut-off: 31-May-2017) ]
    Time to worsening of pain (TTWP) was defined in patients evaluable for assessing worsening of pain, as time from randomization until the first worsening of pain. Patients who died, were lost to follow-up, or ended (MD Anderson Symptom Inventory-Malignant Pleural Mesothelioma) MDASI-MPM assessments without confirmed worsening of pain were censored at the date of their last MDASI-MPM assessment with a non-missing pain score.

  9. Percentage of Participants With Confirmed Improvement of Pain [ Time Frame: Up to approx. 40 months (data cut-off: 06-Apr-2018) - Time from randomization until death from any cause. ]
    Improvement rate of pain was defined as the number of patients with confirmed improvement of pain (based on the "pain at its worst" item of MDASI-MPM), divided by the number of patients evaluable for improvement of pain.

  10. Percentage of Participant With Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to approx. 55 months (data cut-off: 02-Jul-2019) - Time from randomization until 30 days after last treatment (general AEs), or further until death from any cause (selected AEs). ]
    TEAEs were defined as all AEs starting or worsening within the treatment period.

  11. Number of Deaths [ Time Frame: Up to approx. 40 months (data cut-off: 06-Apr-2018) - Time from randomization until death from any cause. ]
    TEAE(s) associated with a fatal outcome (CTCAE Grade 5) at the time of the data cut-off 06-Apr-2018.

  12. Overall Survival (OS) - Addendum [ Time Frame: Up to approx. 55 month (data cut-off: 02-JUL-2019) - Time from randomization until death from any cause ]
    Overall survival (OS) was defined as time from randomization until death from any cause; Only descriptive analyses of OS were repeated in with the data as of the 02 JUL 2019.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological documentation of malignant pleural mesothelioma (MPM) overexpressing mesothelin
  • Unresectable locally advanced or metastatic MPM after locally confirmed progression on 1st line treatment with platinum in combination with pemetrexed.
  • Patients must have measurable disease
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
  • Life expectancy of at least 3 months.
  • Adequate bone marrow, liver and renal function
  • Left ventricular ejection fraction (LVEF) ≥ 50% or the lower limit of normal (LLN) according to local institution ranges of normality.

Exclusion Criteria:

  • More than 1 previous systemic anti-cancer therapy line
  • Patients with corneal epitheliopathy or any eye disorder that may predispose the patients to this condition at the discretion of the investigator in consultation with the ophthalmologist.
  • Brain metastases, meningeal tumours or other metastases in the central nervous system
  • Evidence of history of bleeding diathesis.
  • Ongoing or active infection (bacterial, fungal, or viral) of National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 Grade > 2.
  • Pre-existing cardiac conditions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02610140


Locations
Hide Hide 75 study locations
Layout table for location information
United States, California
La Jolla, California, United States, 92093-1503
United States, Colorado
Aurora, Colorado, United States, 80045
United States, Connecticut
Norwich, Connecticut, United States, 06360
United States, Florida
Tampa, Florida, United States, 33612
United States, Illinois
Chicago, Illinois, United States, 60612
Chicago, Illinois, United States, 60637
United States, Louisiana
New Orleans, Louisiana, United States, 70121
United States, Maryland
Bethesda, Maryland, United States, 20814
United States, Minnesota
Rochester, Minnesota, United States, 55905
United States, New York
Buffalo, New York, United States, 14263-0001
New York, New York, United States, 10016
United States, North Carolina
Durham, North Carolina, United States, 27710
United States, Ohio
Cleveland, Ohio, United States, 44195
United States, Texas
Dallas, Texas, United States, 75251
Houston, Texas, United States, 77030
Australia, New South Wales
St Leonards, New South Wales, Australia, 2065
Australia, Queensland
Woolloogabba, Queensland, Australia, 4102
Australia, South Australia
Adelaide, South Australia, Australia, 5043
Australia, Victoria
Richmond, Victoria, Australia, 3122
Australia, Western Australia
Nedlands, Western Australia, Australia, 6009
Belgium
Bruxelles - Brussel, Belgium, 1200
Edegem, Belgium, 2650
Gent, Belgium, 9000
Leuven, Belgium, 3000
Liege, Belgium, 4000
Sint-niklaas, Belgium, 9100
Canada, Alberta
Calgary, Alberta, Canada, T2N 4N2
Canada, Ontario
Hamilton, Ontario, Canada, L8V 5C2
London, Ontario, Canada, N6A 4L6
Toronto, Ontario, Canada, M5G 2M9
Finland
Helsinki, Finland, 00290
Turku, Finland, 20520
Vaasa, Finland, 65130
France
Bordeaux Cedex, France, 33076
Caen Cedex 5, France, 14076
Lille Cedex, France, 59037
Marseille, France, 13915
Paris, France, 75018
Paris, France, 75020
Pierre Benite, France, 69495
Italy
Pordenone, Friuli-Venezia Giulia, Italy, 33081
Bergamo, Lombardia, Italy, 24125
Milano, Lombardia, Italy, 20089
Milano, Lombardia, Italy, 20133
Monza Brianza, Lombardia, Italy, 20900
Torino, Piemonte, Italy, 10043
Siena, Toscana, Italy, 53100
Korea, Republic of
Seoul, Korea, Republic of, 05505
Seoul, Korea, Republic of, 06351
Netherlands
Amsterdam, Netherlands, 1066 CX
Rotterdam, Netherlands, 3015 CE
Poland
Gdansk, Poland, 80-952
Krakow, Poland, 31-202
Krakow, Poland, 31-501
Szczecin, Poland, 70-891
Russian Federation
Omsk, Russian Federation, 644013
Yekaterinburg, Russian Federation, 620036
Spain
A Coruña, Spain, 15006
Alicante, Spain, 03010
Barcelona, Spain, 08035
Madrid, Spain, 28041
Málaga, Spain, 29010
Turkey
Adana, Turkey, 01330
Ankara, Turkey, 06100
Eskisehir, Turkey, 26480
Istanbul, Turkey, 34899
Malatya, Turkey, 44280
Yenimahalle, Turkey, 06200
United Kingdom
Plymouth, Devon, United Kingdom, PL6 8DH
Maidstone, Kent, United Kingdom, ME16 9QQ
Leicester, Leicestershire, United Kingdom, LE1 5WW
Glasgow, United Kingdom, G12 0YN
London, United Kingdom, SE1 9RT
Manchester, United Kingdom, M23 9LT
Newcastle Upon Tyne, United Kingdom, NE7 7DN
Sponsors and Collaborators
Bayer
ImmunoGen and MorphoSys
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
  Study Documents (Full-Text)

Documents provided by Bayer:
Study Protocol  [PDF] March 27, 2018
Statistical Analysis Plan  [PDF] April 18, 2018

Additional Information:
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02610140    
Other Study ID Numbers: 15743
2012-003650-88 ( EudraCT Number )
First Posted: November 20, 2015    Key Record Dates
Results First Posted: July 17, 2020
Last Update Posted: November 4, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Mesothelioma
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial
Vinorelbine
Maytansine
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action